Market Closed - Nasdaq 16:00:00 2024-05-07 EDT 5-day change 1st Jan Change
90.88 USD -2.65% Intraday chart for BioNTech SE +2.32% -13.89%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
TD Cowen Adjusts BioNTech Price Target to $98 From $95, Maintains Hold Rating MT
BMO Capital Adjusts BioNTech Price Target to $122 From $123, Maintains Outperform Rating MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday MT
BIONTECH : Goldman Sachs reiterates its Neutral rating ZD
Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
Sector Update: Health Care Stocks Advance in Monday Afternoon Trading MT
Sector Update: Health Care MT
BIONTECH : Jefferies gives a Neutral rating ZD
Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco MT
BioNTech Swings to First-Quarter Loss as Lower COVID-19 Commercial Sales Dents Topline MT
Dpa-AFX Overview: COMPANIES from 06.05.2024 - 15:15 DP
Sector Update: Health Care Stocks Gain Pre-Bell Monday MT
Sector Update: Health Care MT
Transcript : BioNTech SE, Q1 2024 Earnings Call, May 06, 2024
BioNTech Swings to Net Loss on Lower Covid Vaccine Sales DJ
BioNTech Swings to Q1 Loss, Revenue Falls -- Shares Decline Pre-Bell MT
Futures Rise Pre-Bell Ahead of Latest Earnings Week; Asia Mostly Up, Europe Strong MT
Inflation, Interest Rate Outlooks Lift Wall Street Pre-Bell; Asia, Europe Up MT
BioNTech says 90% of 2024 revenues will accrue at end of year RE
BioNTech SE Reiterates Revenue Guidance for the Full Year 2024 CI
BioNTech SE Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return DJ
News Highlights : Top Global Markets News of the Day - Monday at 5 AM ET DJ
News Highlights : Top Global Markets News of the Day - Monday at 3 AM ET DJ
News Highlights : Top Global Markets News of the Day - Monday at 1 AM ET DJ
Chart BioNTech SE
More charts
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
86.64 EUR
Average target price
106.6 EUR
Spread / Average Target
+23.08%
Consensus
  1. Stock Market
  2. Equities
  3. BNTX Stock
  4. News BioNTech SE
  5. BioNTech : Redburn Downgrades BioNTech to Sell From Neutral
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW